| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs |  | | 2025 | 56 | 971 |
|
| Case Report : Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation : a case series and literature review | Frontiers in oncology | | | 2025 | 5 | 281 |
|
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | | 2024 | 175 | 1,156 |
|
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | | 2024 | 77 | 253 |
|
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | | 2023 | 54 | 152 |
|
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | | 2023 | 66 | 184 |
|
